Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

The stock's fall snapped a two-day winning streak.

Plc (LSE: GILD), a company recognized for its engagement in competitive gaming, has officially rebranded to Cassell Capital Plc, as confirmed by the issuance of a new Certificate of Incorporation.

At close: January 2 at 11:44:23 a.m. EST ...

Shares closed down in their first day of trading. CEO Shane Smith said the company is at its peak despite threats of tariffs ...

Gildan Activewear Inc. hit a new 52-week high, surpassing its previous peak of C$73.65, which the company achieved on January ...

Fairfax India Holdings Corporation ("Fairfax India" or the "Company") is pleased to announce the voting results from its special meeting of shareholders held on January 28, 2025 (the "Special Meeting" ...